Skip to main content
. 2023 Feb 13;15(2):621. doi: 10.3390/pharmaceutics15020621

Figure 3.

Figure 3

The preparation and characterization of hybrid-cell-membrane-coated nanoparticles for ND drug delivery. (A) The preparation and characterization of DNS-[C6&DC]m for glioma drug delivery; (B) the preparation and characterization of β-PCNPs for glioma drug delivery; (C) the preparation and characterization of NMm-PLGA/RAPA for glioma drug delivery; (D) the preparation and characterization of ISL@HM NPs for glioma drug delivery; and (E) the preparation and characterization of (MSNs/Gboxin)@[RBC-U] for glioma drug delivery.